The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMERGENT BIOSOLUTIONS INC. (EBS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On August 5, 2026, Emergent reported results for the quarter ended June 30, 2026. Among other items, Emergent announced, among other things, a $191.3 million non-cash impairment charge on the NARCAN asset group, driving a GAAP net loss of $180.2 million. The Company also cut full year revenue guidance approximately 10.8% at the midpoint. Management attributed its results to "increased competitive intensity with implications for our near to medium term outlook and the book value of our NARCAN asset group."

On this news, Emergent's stock fell $2.23 per share, or 29.58%, to close at $5.31 on August 6, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Emergent BioSolutions Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260818590185/en/